

Suresh S Ramalingam

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2757389/suresh-s-ramalingam-publications-by-year.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

224
papers

18,928
citations

55
h-index

136
g-index

250
ext. papers

25,104
ext. citations

8.4
avg, IF

6.68
L-index

#	Paper	IF	Citations
224	Protocol of DREAM3R: DuRvalumab with chemotherapy as first-line treatment in advanced pleural mesothelioma—a phase 3 randomised trial. <i>BMJ Open</i> , 2022 , 12, e057663	3	3
223	Bevacizumab Association With a Decreased Risk of Brain Metastases in ECOG-ACRIN E1505, a Phase 3 Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab in Surgically Resected NSCLC. <i>JTO Clinical and Research Reports</i> , 2022 , 3, 100274	1.4	0
222	The novel BET degrader, QCA570, is highly active against the growth of human NSCLC cells and synergizes with osimertinib in suppressing osimertinib-resistant EGFR-mutant NSCLC cells. <i>American Journal of Cancer Research</i> , 2022 , 12, 779-792	4.4	
221	Distinct phenotypic states and spatial distribution of CD8 T cell clonotypes in human brain metastases. <i>Cell Reports Medicine</i> , 2022 , 3, 100620	18	2
220	Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PRE0505 trial. <i>Nature Medicine</i> , 2021 , 27, 1910-1920	50.5	14
219	JASPER: Phase 2 trial of first-line niraparib plus pembrolizumab in patients with advanced non-small cell lung cancer. <i>Cancer</i> , 2021 ,	6.4	6
218	Induction of SREBP1 degradation coupled with suppression of SREBP1-mediated lipogenesis impacts the response of EGFR mutant NSCLC cells to osimertinib. <i>Oncogene</i> , 2021 , 40, 6653-6665	9.2	0
217	Co-Occurrence Conundrum: Brain Metastases from Lung Adenocarcinoma, Radiation Necrosis, and Gliosarcoma. <i>Case Reports in Oncology</i> , 2021 , 14, 487-492	1	1
216	A Review of Immunotherapy for Stage III and Metastatic Non-Small Cell Lung Cancer and the Rationale for the ECOG-ACRIN EA5181 Study. <i>Oncologist</i> , 2021 , 26, 523-532	5.7	1
215	Efficacy and Safety of Glembatumumab Vedotin in Patients With Advanced or Metastatic Squamous Cell Carcinoma of the Lung (PrECOG 0504). <i>JTO Clinical and Research Reports</i> , 2021 , 2, 100166	1.4	1
214	Smoking Behavior in Patients With Early-Stage NSCLC: A Report From ECOG-ACRIN 1505 Trial. <i>Journal of Thoracic Oncology</i> , 2021 , 16, 960-967	8.9	1
213	Advances in Immunotherapy and Implications for Current Practice in Non-Small-Cell Lung Cancer. <i>JCO Oncology Practice</i> , 2021 , 17, 662-668	2.3	3
212	Sotorasib for Lung Cancers with p.G12C Mutation. <i>New England Journal of Medicine</i> , 2021 , 384, 2371-2381	39.2	168
211	Integration of immunotherapy into adjuvant therapy for resected non-small-cell lung cancer: ALCHEMIST chemo-IO (ACCIO). <i>Immunotherapy</i> , 2021 , 13, 727-734	3.8	2
210	Membrane-Associated RING-CH 8 Functions as a Novel PD-L1 E3 Ligase to Mediate PD-L1 Degradation Induced by EGFR Inhibitors. <i>Molecular Cancer Research</i> , 2021 , 19, 1622-1634	6.6	2
209	Abstract CT163: CD73 inhibitor oleclumab plus osimertinib for advanced EGFRm NSCLC: First report of a Phase 1b/2 study 2021 ,		2
208	YAP1 Expression in SCLC Defines a Distinct Subtype With T-cell-Inflamed Phenotype. <i>Journal of Thoracic Oncology</i> , 2021 , 16, 464-476	8.9	23

207	Downregulation of death receptor 4 is tightly associated with positive response of EGFR mutant lung cancer to EGFR-targeted therapy and improved prognosis. <i>Theranostics</i> , 2021 , 11, 3964-3980	12.1	4
206	Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study. <i>Targeted Oncology</i> , 2021 , 16, 165-176	5	18
205	Daratumumab Plus Atezolizumab in Previously Treated Advanced or Metastatic NSCLC: Brief Report on a Randomized, Open-Label, Phase 1b/2 Study (LUC2001 JNJ-54767414). <i>JTO Clinical and Research Reports</i> , 2021 , 2, 100104	1.4	
204	Targeting c-Myc to Overcome Acquired Resistance of EGFR Mutant NSCLC Cells to the Third-Generation EGFR Tyrosine Kinase Inhibitor, Osimertinib. <i>Cancer Research</i> , 2021 , 81, 4822-4834	10.1	5
203	Osimertinib Maintenance After Definitive Chemoradiation in Patients With Unresectable EGFR Mutation Positive Stage III Non-small-cell Lung Cancer: LAURA Trial in Progress. <i>Clinical Lung Cancer</i> , 2021 , 22, 371-375	4.9	7
202	Veliparib in Combination With Platinum-Based Chemotherapy for First-Line Treatment of Advanced Squamous Cell Lung Cancer: A Randomized, Multicenter Phase III Study. <i>Journal of Clinical Oncology</i> , 2021 , 39, 3633-3644	2.2	2
201	Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760) 2021 , 9,		5
200	Expression of tdTomato and luciferase in a murine lung cancer alters the growth and immune microenvironment of the tumor. <i>PLoS ONE</i> , 2021 , 16, e0254125	3.7	1
199	Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer: The Lung-MAP S1400I Phase 3 Randomized Clinical Trial. <i>JAMA Oncology</i> , 2021 , 7, 1368-1377	13.4	6
198	Inhibition of MEK5/ERK5 signaling overcomes acquired resistance to the third generation EGFR inhibitor, osimertinib, via enhancing Bim-dependent apoptosis. <i>Cancer Letters</i> , 2021 , 519, 141-149	9.9	3
197	Treatment Guidance for Patients With Lung Cancer During the Coronavirus 2019 Pandemic. <i>Journal of Thoracic Oncology</i> , 2020 , 15, 1119-1136	8.9	51
196	Fusion: Joining the Ranks of Targetable Molecular Drivers in NSCLC. <i>JTO Clinical and Research Reports</i> , 2020 , 1, 100050	1.4	2
195	MEK or ERK inhibition effectively abrogates emergence of acquired osimertinib resistance in the treatment of epidermal growth factor receptor-mutant lung cancers. <i>Cancer</i> , 2020 , 126, 3788-3799	6.4	14
194	A Phase I Study of Safety, Pharmacokinetics, and Pharmacodynamics of Concurrent Everolimus and Buparlisib Treatment in Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2020 , 26, 2497-2505	12.9	5
193	Reply to N. Hanna et al and L. Xie et al. <i>Journal of Clinical Oncology</i> , 2020 , 38, 771-772	2.2	
192	Trimodality Therapy in the Treatment of Stage III N2-Positive Non-Small Cell Lung Cancer: A National Cancer Database Analysis. <i>Oncologist</i> , 2020 , 25, e964-e975	5.7	7
191	Overcoming acquired resistance of EGFR-mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib, with the natural product honokiol. <i>Molecular Oncology</i> , 2020 , 14, 882-895	7.9	13
190	Prognostic significance of an invasive leader cell-derived mutation cluster on chromosome 16q. <i>Cancer</i> , 2020 , 126, 3140-3150	6.4	1

189	Durvalumab and tremelimumab with or without stereotactic body radiation therapy in relapsed small cell lung cancer: a randomized phase II study 2020 , 8,		13
188	Randomized phase II clinical trial of cisplatin/carboplatin and etoposide (CE) alone or in combination with nivolumab as frontline therapy for extensive-stage small cell lung cancer (ES-SCLC): ECOG-ACRIN EA5161.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 9000-9000	2.2	45
187	PrE0505: Phase II multicenter study of anti-PD-L1, durvalumab, in combination with cisplatin and pemetrexed for the first-line treatment of unresectable malignant pleural mesothelioma (MPM) A PrECOG LLC study.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 9003-9003	2.2	21
186	YAP1 positive small-cell lung cancer subtype is associated with the T-cell inflamed gene expression profile and confers good prognosis and long term survival.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 9019-9019	2.2	4
185	ECOG-ACRIN 5162: A phase II study of osimertinib 160 mg in NSCLC with EGFR exon 20 insertions.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 9513-9513	2.2	36
184	Nivolumab (NIVO) plus ipilimumab (IPI) with two cycles of chemotherapy (chemo) in first-line metastatic non-small cell lung cancer (NSCLC): CheckMate 568 Part 2.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 9560-9560	2.2	1
183	Lung-MAP (SWOG S1400): Design, implementation, and lessons learned from a biomarker-driven master protocol (BDMP) for previously-treated squamous lung cancer (sqNSCLC).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 9576-9576	2.2	0
182	High-dose osimertinib for CNS progression in EGFR+ non-small cell lung cancer (NSCLC): A multi-institutional experience.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 9586-9586	2.2	10
181	Interim results of prospective pilot phase II trial of concurrent anti-PD-1 and stereotactic radiosurgery (SRS) for melanoma and NSCLC patients with brain metastases (NCT02858869).. <i>Journal of Clinical Oncology</i> , 2020 , 38, e22002-e22002	2.2	3
180	ALCHEMIST: Adjuvant targeted therapy or immunotherapy for high-risk resected NSCLC.. <i>Journal of Clinical Oncology</i> , 2020 , 38, TPS9077-TPS9077	2.2	11
179	SWOG S1400F (NCT03373760): A phase II study of durvalumab plus tremelimumab for previously treated patients with acquired resistance to PD-1 checkpoint inhibitor therapy and stage IV squamous cell lung cancer (Lung-MAP Sub-study).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 9623-9623	2.2	
178	Utilization patterns of immune checkpoint inhibitors (ICI) for non-small cell lung cancer (NSCLC) within the veterans health administration (VHA).. <i>Journal of Clinical Oncology</i> , 2020 , 38, e21630-e21630	2.2	
177	A phase I study of ADXS-503 alone and in combination with pembrolizumab in subjects with metastatic squamous or non-squamous non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2020 , 38, e21682-e21682	2.2	2
176	Clinical performance of a comprehensive novel liquid biopsy test for identifying non-small cell lung cancer (NSCLC) patients for treatment with osimertinib.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 9553-9553	2.2	1
175	Double immune checkpoint blockade in advanced NSCLC. <i>Critical Reviews in Oncology/Hematology</i> , 2020 , 152, 102980	7	8
174	The International Association for the Study of Lung Cancer Global Survey on Molecular Testing in Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2020 , 15, 1434-1448	8.9	42
173	Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer. <i>Lung Cancer</i> , 2020 , 139, 60-67	5.9	48
172	Combined Effect of Sarcopenia and Systemic Inflammation on Survival in Patients with Advanced Stage Cancer Treated with Immunotherapy. <i>Oncologist</i> , 2020 , 25, e528-e535	5.7	26

171	ERK inhibition effectively overcomes acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib. <i>Cancer</i> , 2020 , 126, 1339-1350	6.4	22
170	Overall Survival with Osimertinib in Untreated, -Mutated Advanced NSCLC. <i>New England Journal of Medicine</i> , 2020 , 382, 41-50	59.2	771
169	Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial: Osimertinib versus platinum-pemetrexed for T790M mutation-positive advanced non-small cell lung cancer. <i>Cancer</i> , 2020 , 126, 373-380	6.4	47
168	Inhibition of ACK1 delays and overcomes acquired resistance of EGFR mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib. <i>Lung Cancer</i> , 2020 , 150, 26-35	5.9	1
167	Phase II Study of Immunotherapy With Tecemotide and Bevacizumab After Chemoradiation in Patients With Unresectable Stage III Non-Squamous Non-Small-Cell Lung Cancer (NS-NSCLC): A Trial of the ECOG-ACRIN Cancer Research Group (E6508). <i>Clinical Lung Cancer</i> , 2020 , 21, 520-526	4.9	3
166	Phase 1 safety and pharmacodynamic study of lenalidomide combined with everolimus in patients with advanced solid malignancies with efficacy signal in adenoid cystic carcinoma. <i>British Journal of Cancer</i> , 2020 , 123, 1228-1234	8.7	1
165	Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol. <i>Lancet Oncology</i> , 2020 , 21, 1589-1601	21.7	26
164	Targeting -Mutant Non-Small-Cell Lung Cancer: One Mutation at a Time, With a Focus on Mutations. <i>Journal of Clinical Oncology</i> , 2020 , 38, 4208-4218	2.2	12
163	Efficacy and safety of immune checkpoint blockade in self-identified Black patients with advanced non-small cell lung cancer. <i>Cancer</i> , 2020 , 126, 5040-5049	6.4	3
162	Phase Ib Study of Chemoprevention with Green Tea Polyphenon E and Erlotinib in Patients with Advanced Premalignant Lesions (APL) of the Head and Neck. <i>Clinical Cancer Research</i> , 2020 , 26, 5860-5868	12.9	4
161	KRAS Inhibition with Sotorasib in Advanced Solid Tumors. <i>New England Journal of Medicine</i> , 2020 , 383, 1207-1217	59.2	469
160	Guidance on the Clinical Management of Electronic Cigarette or Vaping-Associated Lung Injury. <i>Journal of Thoracic Oncology</i> , 2020 , 15, 1727-1737	8.9	3
159	Adiposity may predict survival in patients with advanced stage cancer treated with immunotherapy in phase 1 clinical trials. <i>Cancer</i> , 2020 , 126, 575-582	6.4	24
158	Programmed Cell Death Ligand 1 Expression in Untreated EGFR Mutated Advanced NSCLC and Response to Osimertinib Versus Comparator in FLAURA. <i>Journal of Thoracic Oncology</i> , 2020 , 15, 138-143	8.9	18
157	Overcoming acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib by combining osimertinib with the histone deacetylase inhibitor panobinostat (LBH589). <i>Cancer</i> , 2020 , 126, 2024-2033	6.4	19
156	Sites of metastasis and association with clinical outcome in advanced stage cancer patients treated with immunotherapy. <i>BMC Cancer</i> , 2019 , 19, 857	4.8	46
155	Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2019 , 25, 6644-6652	12.9	53
154	Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2019 , 381, 2020-2031	59.2	960

153	Role of osimertinib in the treatment of EGFR-mutation positive non-small-cell lung cancer. <i>Future Oncology</i> , 2019 , 15, 805-816	3.6	18
152	Survival Outcomes With Thoracic Radiotherapy in Extensive-Stage Small-Cell Lung Cancer: A Propensity Score-Matched Analysis of the National Cancer Database. <i>Clinical Lung Cancer</i> , 2019 , 20, 484-493.e6	4.9	11
151	DNA-PKc deficiency drives pre-malignant transformation by reducing DNA repair capacity in concert with reprogramming the epigenome in human bronchial epithelial cells. <i>DNA Repair</i> , 2019 , 79, 1-9	4.3	5
150	Pharmacokinetic Study of Osimertinib in Cancer Patients with Mild or Moderate Hepatic Impairment. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2019 , 369, 291-299	4.7	6
149	Characteristics and Outcomes of Patients With Metastatic KRAS-Mutant Lung Adenocarcinomas: The Lung Cancer Mutation Consortium Experience. <i>Journal of Thoracic Oncology</i> , 2019 , 14, 876-889	8.9	74
148	Concurrent chemoradiotherapy with weekly versus triweekly cisplatin in locally advanced squamous cell carcinoma of the head and neck: Comparative analysis. <i>Head and Neck</i> , 2019 , 41, 1490-1498 ²	4.2	14
147	A new standard of care for patients with surgically unresectable stage III non-small cell lung cancer. <i>Cancer</i> , 2019 , 125, 2148-2153	6.4	0
146	The Third-Generation EGFR Inhibitor, Osimertinib, Promotes c-FLIP Degradation, Enhancing Apoptosis Including TRAIL-Induced Apoptosis in NSCLC Cells with Activating EGFR Mutations. <i>Translational Oncology</i> , 2019 , 12, 705-713	4.9	7
145	Randomized Phase II Trial of Cisplatin and Etoposide in Combination With Veliparib or Placebo for Extensive-Stage Small-Cell Lung Cancer: ECOG-ACRIN 2511 Study. <i>Journal of Clinical Oncology</i> , 2019 , 37, 222-229	2.2	75
144	Clinical outcomes of advanced stage cancer patients treated with sequential immunotherapy in phase 1 clinical trials. <i>Investigational New Drugs</i> , 2019 , 37, 1198-1206	4.3	8
143	Inhibition of mTOR complex 1/p70 S6 kinase signaling elevates PD-L1 levels in human cancer cells through enhancing protein stabilization accompanied with enhanced ETRCP degradation. <i>Oncogene</i> , 2019 , 38, 6270-6282	9.2	28
142	Phase 1 study of veliparib (ABT-888), a poly (ADP-ribose) polymerase inhibitor, with carboplatin and paclitaxel in advanced solid malignancies. <i>Cancer Chemotherapy and Pharmacology</i> , 2019 , 84, 1289-1301	3.5	18
141	Postprogression Outcomes for Osimertinib versus Standard-of-Care EGFR-TKI in Patients with Previously Untreated EGFR-mutated Advanced Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2019 , 25, 2058-2063	12.9	36
140	Osimertinib versus Standard of Care EGFR TKI as First-Line Treatment in Patients with EGFRm Advanced NSCLC: FLAURA Asian Subset. <i>Journal of Thoracic Oncology</i> , 2019 , 14, 99-106	8.9	44
139	The prognostic and predictive impact of inflammatory biomarkers in patients who have advanced-stage cancer treated with immunotherapy. <i>Cancer</i> , 2019 , 125, 127-134	6.4	71
138	A banner year for immunotherapy and targeted therapy. <i>Nature Reviews Clinical Oncology</i> , 2019 , 16, 79-80	19.4	13
137	Osimertinib in patients with T790M mutation-positive, advanced non-small cell lung cancer: Long-term follow-up from a pooled analysis of 2 phase 2 studies. <i>Cancer</i> , 2019 , 125, 892-901	6.4	78
136	Update on International Cooperative Groups Studies in Thoracic Malignancies: The Emergence of Immunotherapy. <i>Clinical Lung Cancer</i> , 2018 , 19, 377-386	4.9	

135	Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden. <i>New England Journal of Medicine</i> , 2018 , 378, 2093-2104	59.2	1704
134	CD8 T Cell Exhaustion in Chronic Infection and Cancer: Opportunities for Interventions. <i>Annual Review of Medicine</i> , 2018 , 69, 301-318	17.4	265
133	Efficacy and Safety of Ramucirumab With Docetaxel Versus Placebo With Docetaxel as Second-Line Treatment of Advanced Non-Small-Cell Lung Cancer: A Subgroup Analysis According to Patient Age in the REVEL Trial. <i>Clinical Lung Cancer</i> , 2018 , 19, 270-279.e3	4.9	6
132	Current and Emergent Therapy Options for Advanced Squamous Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018 , 13, 165-183	8.9	52
131	Health care disparities among octogenarians and nonagenarians with stage III lung cancer. <i>Cancer</i> , 2018 , 124, 775-784	6.4	18
130	Impact of a Non-small Cell Lung Cancer Educational Program for Interdisciplinary Teams. <i>Chest</i> , 2018 , 153, 876-887	5.3	6
129	Osimertinib in EGFR Mutation-Positive Advanced NSCLC. <i>New England Journal of Medicine</i> , 2018 , 378, 1262-1263	59.2	16
128	Molecular and Immune Biomarker Testing in Squamous-Cell Lung Cancer: Effect of Current and Future Therapies and Technologies. <i>Clinical Lung Cancer</i> , 2018 , 19, 331-339	4.9	13
127	Overexpression of the base excision repair NTHL1 glycosylase causes genomic instability and early cellular hallmarks of cancer. <i>Nucleic Acids Research</i> , 2018 , 46, 4515-4532	20.1	21
126	Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer: A systematic analysis of the literature. <i>Cancer</i> , 2018 , 124, 271-277	6.4	173
125	Common cancer-driver mutations and their association with abnormally methylated genes in lung adenocarcinoma from never-smokers. <i>Lung Cancer</i> , 2018 , 123, 99-106	5.9	5
124	Targeted sequencing and intracranial outcomes of patients with lung adenocarcinoma brain metastases treated with radiotherapy. <i>Cancer</i> , 2018 , 124, 3586-3595	6.4	2
123	Race-, Age-, and Gender-Based Characteristics and Toxicities of Targeted Therapies on Phase I Trials. <i>Oncology</i> , 2018 , 95, 138-146	3.6	5
122	Early clearance of plasma EGFR mutations as a predictor of response to osimertinib in the AURA3 trial.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 9027-9027	2.2	18
121	Safety and efficacy of combining pembrolizumab and dose escalation/fraction de-escalation SRS for melanoma and NSCLC brain metastasis: Preliminary results from arm a of a prospective pilot trial.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e21542-e21542	2.2	1
120	The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations-The Lung Cancer Mutation Consortium (LCMC2). <i>Clinical Cancer Research</i> , 2018 , 24, 1038-1047	12.9	100
119	Immune checkpoint inhibitors in advanced non-small cell lung cancer. <i>Cancer</i> , 2018 , 124, 248-261	6.4	65
118	Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2018 , 378, 113-125	59.2	2098

117	Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2018 , 36, 841-849	2.2	291
116	CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2018 , JCO2018783118	2.2	284
115	Immunotherapy in previously treated non-small cell lung cancer (NSCLC). <i>Journal of Thoracic Disease</i> , 2018 , 10, S422-S432	2.6	6
114	Radiation Therapy Is Associated With an Increased Incidence of Cardiac Events in Patients with Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018 , 102, 383-390	4	9
113	Discussing molecular testing in oncology care: Comparing patient and physician information preferences. <i>Cancer</i> , 2017 , 123, 1610-1616	6.4	12
112	Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1288-1296	2.2	363
111	Assays for PD-L1 Expression: Do All Roads Lead to Rome?. <i>JAMA Oncology</i> , 2017 , 3, 1058-1059	13.4	4
110	Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent. <i>Science</i> , 2017 , 355, 1423-1427	3.5	486
109	Using Metaphors to Explain Molecular Testing to Cancer Patients. <i>Oncologist</i> , 2017 , 22, 445-449	5.7	7
108	Plasma ctDNA Analysis for Detection of the EGFR T790M Mutation in Patients with Advanced Non-Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017 , 12, 1061-1070	8.9	178
107	Concurrent chemoradiotherapy with or without surgery for patients with resectable esophageal cancer: An analysis of the National Cancer Data Base. <i>Cancer</i> , 2017 , 123, 3476-3485	6.4	27
106	Guideline-concordant Care Improves Overall Survival for Locally Advanced Non-Small-cell Lung Carcinoma Patients: A National Cancer Database Analysis. <i>Clinical Lung Cancer</i> , 2017 , 18, 706-718	4.9	12
105	Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1-targeted therapy in lung cancer patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017 , 114, 4993-4998	11.5	375
104	Smoking History Predicts Sensitivity to PARP Inhibitor Veliparib in Patients with Advanced Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017 , 12, 1098-1108	8.9	14
103	Epidermal Growth Factor Receptor Mutated Advanced Non-Small Cell Lung Cancer: A Changing Treatment Paradigm. <i>Hematology/Oncology Clinics of North America</i> , 2017 , 31, 83-99	3.1	9
102	Access to Cancer Specialist Care and Treatment in Patients With Advanced Stage Lung Cancer. <i>Clinical Lung Cancer</i> , 2017 , 18, 640-650.e2	4.9	4
101	Next-generation sequencing and clinical outcomes of patients with lung adenocarcinoma treated with stereotactic body radiotherapy. <i>Cancer</i> , 2017 , 123, 3681-3690	6.4	27
100	Stereotactic Body Radiotherapy for Early-stage Non-small-cell Lung Cancer in Patients 80 Years and Older: A Multi-center Analysis. <i>Clinical Lung Cancer</i> , 2017 , 18, 551-558.e6	4.9	20

99	Modulation of Bax and mTOR for Cancer Therapeutics. <i>Cancer Research</i> , 2017 , 77, 3001-3012	10.1	17
98	Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. <i>New England Journal of Medicine</i> , 2017 , 376, 629-640	59.2	1811
97	Pulmonary Sarcomatoid Carcinoma: An Analysis of the National Cancer Data Base. <i>Clinical Lung Cancer</i> , 2017 , 18, 286-292	4.9	34
96	American Society of Clinical Oncology Policy Brief: FDA's Regulation of Electronic Nicotine Delivery Systems and Tobacco Products. <i>Journal of Oncology Practice</i> , 2017 , 13, 58-60	3.1	3
95	Gene Methylation Biomarkers in Sputum and Plasma as Predictors for Lung Cancer Recurrence. <i>Cancer Prevention Research</i> , 2017 , 10, 635-640	3.2	10
94	HER2 mutations in lung adenocarcinomas: A report from the Lung Cancer Mutation Consortium. <i>Cancer</i> , 2017 , 123, 4099-4105	6.4	85
93	Overcoming Acquired Resistance to AZD9291, A Third-Generation EGFR Inhibitor, through Modulation of MEK/ERK-Dependent Bim and Mcl-1 Degradation. <i>Clinical Cancer Research</i> , 2017 , 23, 6567-6579	12.9	75
92	Thoracic Oncology Clinical Trial Eligibility Criteria and Requirements Continue to Increase in Number and Complexity. <i>Journal of Thoracic Oncology</i> , 2017 , 12, 1489-1495	8.9	27
91	Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial. <i>Lancet Oncology</i> , 2017 , 18, 1610-1623	21.7	95
90	Concomitant Chemotherapy and Radiotherapy with SBRT Boost for Unresectable Stage III Non-Small Cell Lung Cancer: A Phase I Study. <i>Journal of Thoracic Oncology</i> , 2017 , 12, 1687-1695	8.9	29
89	National Cancer Database Analysis of Proton Versus Photon Radiation Therapy in Non-Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017 , 97, 128-137	4	80
88	Cardiac allograft rejection as a complication of PD-1 checkpoint blockade for cancer immunotherapy: a case report. <i>Cancer Immunology, Immunotherapy</i> , 2017 , 66, 45-50	7.4	44
87	Overview of Thoracic Oncology Trials in Cooperative Groups Around the Globe. <i>Clinical Lung Cancer</i> , 2017 , 18, 5-12	4.9	2
86	Randomized, Placebo-Controlled, Phase II Study of Veliparib in Combination with Carboplatin and Paclitaxel for Advanced/Metastatic Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2017 , 23, 1937-1944	12.9	52
85	Targeting adhesion signaling in mutant lung adenocarcinoma. <i>JCI Insight</i> , 2017 , 2, e90487	9.9	21
84	Characteristics and outcomes of patients (pts) with metastatic KRAS mutant lung adenocarcinomas: Lung Cancer Mutation Consortium (LCMC) database.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 9021-9021	2.2	11
83	GCT1021-01, a first-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of Axl-specific antibody-drug conjugate (HuMax-Axl-ADC) in patients with solid tumors (NCT02988817).. <i>Journal of Clinical Oncology</i> , 2017 , 35, TPS2605-TPS2605	2.2	5
82	Gene methylation biomarkers in sputum as a classifier for lung cancer risk. <i>Oncotarget</i> , 2017 , 8, 63978-63985	3.2	11

81	Impact of prior radiation on survival in metastatic lung cancer ECOG-ACRIN trials.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 9051-9051	2.2	
80	Phase IB study of induction chemotherapy with XELOX, followed by radiation therapy, carboplatin, and everolimus in patients with locally advanced esophageal cancer (EC).. <i>Journal of Clinical Oncology</i> , 2017 , 35, e15607-e15607	2.2	
79	Health care disparities among octogenarians and nonagenarians with stage III lung cancer.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e18075-e18075	2.2	1
78	Trends, predictors, and impact of systemic chemotherapy in small cell lung cancer patients between 1985 and 2005. <i>Cancer</i> , 2016 , 122, 50-60	6.4	30
77	Incremental Innovation and Progress in Advanced Squamous Cell Lung Cancer: Current Status and Future Impact of Treatment. <i>Journal of Thoracic Oncology</i> , 2016 , 11, 2066-2081	8.9	40
76	Enrollment Trends and Disparity Among Patients With Lung Cancer in National Clinical Trials, 1990 to 2012. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3992-3999	2.2	60
75	Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment. <i>Cancer Letters</i> , 2016 , 380, 494-504	9.9	102
74	Small-Cell Lung Cancer: New Directions for Systemic Therapy. <i>Journal of Oncology Practice</i> , 2016 , 12, 119-20	3.1	4
73	Clinicopathologic Features of Advanced Squamous NSCLC. <i>Journal of Thoracic Oncology</i> , 2016 , 11, 1411-82	8.9	57
72	Role of race in oncogenic driver prevalence and outcomes in lung adenocarcinoma: Results from the Lung Cancer Mutation Consortium. <i>Cancer</i> , 2016 , 122, 766-72	6.4	65
71	Clinical Validation and Implementation of a Targeted Next-Generation Sequencing Assay to Detect Somatic Variants in Non-Small Cell Lung, Melanoma, and Gastrointestinal Malignancies. <i>Journal of Molecular Diagnostics</i> , 2016 , 18, 299-315	5.1	45
70	Scientific Advances in Lung Cancer 2015. <i>Journal of Thoracic Oncology</i> , 2016 , 11, 613-638	8.9	164
69	Isolating the Role of Bevacizumab in Elderly Patients With Previously Untreated Nonsquamous Non-Small Cell Lung Cancer: Secondary Analyses of the ECOG 4599 and PointBreak Trials. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2016 , 39, 441-7	2.7	35
68	Lung Adenocarcinoma Staging Using the 2011 IASLC/ATS/ERS Classification: A Pooled Analysis of Adenocarcinoma In Situ and Minimally Invasive Adenocarcinoma. <i>Clinical Lung Cancer</i> , 2016 , 17, e57-e64	4.9	44
67	Evaluating Intensity-Modulated Radiation Therapy in Locally Advanced Non-Small-Cell Lung Cancer: Results From the National Cancer Data Base. <i>Clinical Lung Cancer</i> , 2016 , 17, 398-405	4.9	34
66	Patient-derived xenografts faithfully replicated clinical outcome in a phase II co-clinical trial of arsenic trioxide in relapsed small cell lung cancer. <i>Journal of Translational Medicine</i> , 2016 , 14, 111	8.5	58
65	EGFR Fusions as Novel Therapeutic Targets in Lung Cancer. <i>Cancer Discovery</i> , 2016 , 6, 601-11	24.4	65
64	Metastatic Lung Cancer: Emerging Therapeutic Strategies. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2016 , 37, 736-749	3.9	1

63	The next generation of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of lung cancer. <i>Cancer</i> , 2015 , 121, E1-6	6.4	47
62	Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. <i>Lancet Oncology</i> , 2015 , 16, 257-65	21.7	1050
61	Nonclinical Factors Associated with 30-Day Mortality after Lung Cancer Resection: An Analysis of 215,000 Patients Using the National Cancer Data Base. <i>Journal of the American College of Surgeons</i> , 2015 , 221, 550-63	4.4	25
60	Racial disparities in squamous cell carcinoma of the oral tongue among women: a SEER data analysis. <i>Oral Oncology</i> , 2015 , 51, 586-92	4.4	39
59	Predictors and outcomes of venous thromboembolism in hospitalized lung cancer patients: A Nationwide Inpatient Sample database analysis. <i>Lung Cancer</i> , 2015 , 88, 80-4	5.9	16
58	Genetic Testing and Tissue Banking for Personalized Oncology: Analytical and Institutional Factors. <i>Seminars in Oncology</i> , 2015 , 42, 713-23	5.5	10
57	Necitumumab in Metastatic Squamous Cell Lung Cancer: Establishing a Value-Based Cost. <i>JAMA Oncology</i> , 2015 , 1, 1293-300	13.4	33
56	Treatment of Small-Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians Guideline. <i>Journal of Clinical Oncology</i> , 2015 , 33, 4106-11	2.2	184
55	Management and Outcomes of Hospitalized Patients With Primary Neuroendocrine Tumor and Non-Neuroendocrine Tumor Appendiceal Cancers in the United States. <i>World Journal of Oncology</i> , 2015 , 6, 349-354	16.7	
54	Small-Molecule Bcl2 BH4 Antagonist for Lung Cancer Therapy. <i>Cancer Cell</i> , 2015 , 27, 852-63	24.3	86
53	Targeting EGFR in lung cancer: Lessons learned and future perspectives. <i>Molecular Aspects of Medicine</i> , 2015 , 45, 67-73	16.7	34
52	ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2015 , 21, 5439-44	12.9	76
51	Randomized phase II study of carboplatin and paclitaxel with either linifanib or placebo for advanced nonsquamous non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2015 , 33, 433-41	2.2	36
50	A Translational, Pharmacodynamic, and Pharmacokinetic Phase IB Clinical Study of Everolimus in Resectable Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2015 , 21, 1859-68	12.9	20
49	Socioeconomic risk factors for long-term mortality after pulmonary resection for lung cancer: an analysis of more than 90,000 patients from the National Cancer Data Base. <i>Journal of the American College of Surgeons</i> , 2015 , 220, 156-168.e4	4.4	28
48	Lung Master Protocol (Lung-MAP)-A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400. <i>Clinical Cancer Research</i> , 2015 , 21, 1514-24	12.9	165
47	Combination of heat shock protein 90 and focal adhesion kinase inhibitors synergistically inhibits the growth of non-small cell lung cancer cells. <i>Oncoscience</i> , 2015 , 2, 765-776	0.8	9
46	ALK-positive non-small cell lung cancer: mechanisms of resistance and emerging treatment options. <i>Cancer</i> , 2014 , 120, 2392-402	6.4	46

45	Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/International Association for the study of lung cancer/association for molecular pathology guideline. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3673-9	2.2	213
44	Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial. <i>Lancet Oncology</i> , 2014 , 15, 1369-78	21.7	109
43	HPV-associated lung cancers: an international pooled analysis. <i>Carcinogenesis</i> , 2014 , 35, 1267-75	4.6	49
42	Concurrent therapy with taxane versus non-taxane containing regimens in locally advanced squamous cell carcinomas of the head and neck (SCCHN): a systematic review. <i>Oral Oncology</i> , 2014 , 50, 888-94	4.4	15
41	Second-generation ALK inhibitors: filling the non "MET" gap. <i>Cancer Discovery</i> , 2014 , 4, 634-6	24.4	7
40	Phase 1 and pharmacokinetic study of everolimus in combination with cetuximab and carboplatin for recurrent/metastatic squamous cell carcinoma of the head and neck. <i>Cancer</i> , 2014 , 120, 3940-51	6.4	39
39	Poly (ADP) ribose polymerase enzyme inhibitor, veliparib, potentiates chemotherapy and radiation in vitro and in vivo in small cell lung cancer. <i>Cancer Medicine</i> , 2014 , 3, 1579-94	4.8	58
38	Comparison of survival and hospitalization rates between Medicare patients with advanced NSCLC treated with bevacizumab-carboplatin-paclitaxel and carboplatin-paclitaxel: a retrospective cohort study. <i>Lung Cancer</i> , 2014 , 86, 350-7	5.9	9
37	Advances in the diagnosis and treatment of non-small cell lung cancer. <i>Molecular Cancer Therapeutics</i> , 2014 , 13, 557-64	6.1	15
36	Phase II study of docetaxel in combination with everolimus for second- or third-line therapy of advanced non-small-cell lung cancer. <i>Journal of Thoracic Oncology</i> , 2013 , 8, 369-72	8.9	35
35	Carboplatin (C), cetuximab (Cet), and everolimus (E) in recurrent or metastatic squamous cell carcinoma of the head and neck (RMSCCHN). Results of a phase Ib study.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 6083-6083	2.2	1
34	Adherence reporting in phase III trials of approved oral anticancer agents: A systematic review.. <i>Journal of Clinical Oncology</i> , 2013 , 31, e20596-e20596	2.2	1
33	Prophylactic cranial irradiation in patients ≥ 70 years old with limited stage small cell lung cancer: A Surveillance, Epidemiology, and End Results analysis.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 7589-7589	2.2	
32	Human immunodeficiency virus-associated lung cancer in the era of highly active antiretroviral therapy. <i>Cancer</i> , 2012 , 118, 164-72	6.4	29
31	The combination of RAD001 and NVP-BKM120 synergistically inhibits the growth of lung cancer in vitro and in vivo. <i>Cancer Letters</i> , 2012 , 325, 139-46	9.9	49
30	The biology and clinical features of non-small cell lung cancers with EML4-ALK translocation. <i>Current Oncology Reports</i> , 2012 , 14, 105-10	6.3	32
29	Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2012 , 30, 3337-44	2.2	214
28	Histone deacetylase inhibitors. <i>Journal of Thoracic Oncology</i> , 2011 , 6, S1808-9	8.9	1

27	Bortezomib for patients with advanced-stage bronchioloalveolar carcinoma: a California Cancer Consortium Phase II study (NCI 7003). <i>Journal of Thoracic Oncology</i> , 2011 , 6, 1741-5	8.9	9
26	Lung cancer: New biological insights and recent therapeutic advances. <i>Ca-A Cancer Journal for Clinicians</i> , 2011 , 61, 91-112	220.7	329
25	Randomized phase II study of erlotinib in combination with placebo or R1507, a monoclonal antibody to insulin-like growth factor-1 receptor, for advanced-stage non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2011 , 29, 4574-80	2.2	109
24	Cetuximab for the treatment of advanced bronchioloalveolar carcinoma (BAC): an Eastern Cooperative Oncology Group phase II study (ECOG 1504). <i>Journal of Clinical Oncology</i> , 2011 , 29, 1709-14	2.2	20
23	Histone deacetylase, proteasome, and heat shock protein inhibitors for the treatment of lung cancer. <i>Journal of Thoracic Oncology</i> , 2010 , 5, S458-60	8.9	2
22	Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2010 , 28, 56-62	2.2	224
21	Phase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study. <i>Journal of Clinical Oncology</i> , 2010 , 28, 4507-12	2.2	77
20	Phase II study of Cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (National Cancer Institute #7097). <i>Journal of Thoracic Oncology</i> , 2010 , 5, 1279-84	8.9	66
19	Phase 2 study of irinotecan and paclitaxel in patients with recurrent or refractory small cell lung cancer. <i>Cancer</i> , 2010 , 116, 1344-9	6.4	12
18	Phase 1 and pharmacokinetic study of everolimus, a mammalian target of rapamycin inhibitor, in combination with docetaxel for recurrent/refractory nonsmall cell lung cancer. <i>Cancer</i> , 2010 , 116, 3903-9	6.4	35
17	Phosphorylated eukaryotic translation initiation factor 4 (eIF4E) is elevated in human cancer tissues. <i>Cancer Biology and Therapy</i> , 2009 , 8, 1463-9	4.6	86
16	The role of the taxanes in the treatment of older patients with advanced stage non-small cell lung cancer. <i>Oncologist</i> , 2009 , 14, 412-24	5.7	12
15	Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma. <i>Journal of Thoracic Oncology</i> , 2009 , 4, 97-101	8.9	148
14	Overcoming mTOR inhibition-induced paradoxical activation of survival signaling pathways enhances mTOR inhibitors' anticancer efficacy. <i>Cancer Biology and Therapy</i> , 2008 , 7, 1952-8	4.6	78
13	Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions. <i>Oncologist</i> , 2008 , 13 Suppl 1, 5-13	5.7	262
12	A phase I study of 17-allylamino-17-demethoxygeldanamycin combined with paclitaxel in patients with advanced solid malignancies. <i>Clinical Cancer Research</i> , 2008 , 14, 3456-61	12.9	61
11	Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599. <i>Journal of Clinical Oncology</i> , 2008 , 26, 60-5	2.2	301
10	Recent advances in the treatment of malignant pleural mesothelioma. <i>Journal of Thoracic Oncology</i> , 2008 , 3, 1056-64	8.9	21

9	The role of targeted agents in the treatment of elderly patients with non-small cell lung cancer (NSCLC). <i>Current Treatment Options in Oncology</i> , 2008 , 9, 313-25	5.4	2
8	Lung cancer in elderly patients: an analysis of the surveillance, epidemiology, and end results database. <i>Journal of Clinical Oncology</i> , 2007 , 25, 5570-7	2.2	403
7	Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies. <i>Clinical Cancer Research</i> , 2007 , 13, 3605-10	12.9	168
6	Role of bevacizumab for the treatment of non-small-cell lung cancer. <i>Future Oncology</i> , 2007 , 3, 131-9	3.6	11
5	Recent advances in targeted therapy for non-small cell lung cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2007 , 11, 245-57	6.4	24
4	Molecularly-targeted therapies for non-small cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2005 , 6, 2667-79	4	5
3	Exploring the future of non-small cell lung cancer treatment. <i>Managed Care</i> , 2005 , 14, 9-13; discussion 13-4	0.3	
2	Lung203-220		
1	Lung203-220		1